Eric J. Stanek

3.0k total citations
58 papers, 2.1k citations indexed

About

Eric J. Stanek is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Eric J. Stanek has authored 58 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cardiology and Cardiovascular Medicine, 19 papers in Surgery and 16 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Eric J. Stanek's work include Lipoproteins and Cardiovascular Health (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers). Eric J. Stanek is often cited by papers focused on Lipoproteins and Cardiovascular Health (11 papers), Health Systems, Economic Evaluations, Quality of Life (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (7 papers). Eric J. Stanek collaborates with scholars based in United States, France and Austria. Eric J. Stanek's co-authors include Todd C. Villines, Allen J. Taylor, Michael Miller, Neil J. Weissman, Mark Turco, Patrick J. Devine, Felix W. Frueh, Robert S. Epstein, Ronald E. Aubert and Barnabie Agatep and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Eric J. Stanek

57 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eric J. Stanek United States	19	724	609	477	340	292	58	2.1k
Antonio González‐Pérez Spain	27	678 0.9×	618 1.0×	249 0.5×	143 0.4×	102 0.3×	69	2.8k
George A. Stouffer United States	36	1.1k 1.5×	2.0k 3.2×	391 0.8×	207 0.6×	170 0.6×	187	4.0k
Damiano Baldassarre Italy	28	890 1.2×	1.5k 2.5×	687 1.4×	284 0.8×	78 0.3×	95	3.1k
Danish Saleheen Pakistan	22	796 1.1×	782 1.3×	561 1.2×	297 0.9×	35 0.1×	45	2.4k
Anna I. Kakafika Greece	28	1.0k 1.4×	496 0.8×	858 1.8×	84 0.2×	56 0.2×	57	2.3k
Eugen Steiner Sweden	16	980 1.4×	500 0.8×	1.1k 2.3×	66 0.2×	370 1.3×	25	2.3k
Peter Lansberg Netherlands	24	1.8k 2.4×	686 1.1×	692 1.5×	123 0.4×	43 0.1×	37	2.3k
Jong-Soon Park United States	12	793 1.1×	375 0.6×	632 1.3×	173 0.5×	38 0.1×	27	1.7k
Dimitrios Tziakas Greece	27	404 0.6×	909 1.5×	157 0.3×	256 0.8×	124 0.4×	102	2.1k
Evan A. Stein United States	27	2.6k 3.6×	818 1.3×	1.7k 3.6×	297 0.9×	105 0.4×	59	4.7k

Countries citing papers authored by Eric J. Stanek

Since Specialization

Citations

This map shows the geographic impact of Eric J. Stanek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Stanek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Stanek more than expected).

Fields of papers citing papers by Eric J. Stanek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Stanek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Stanek. The network helps show where Eric J. Stanek may publish in the future.

Co-authorship network of co-authors of Eric J. Stanek

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Stanek. A scholar is included among the top collaborators of Eric J. Stanek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Stanek. Eric J. Stanek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Visaria, Jay, et al.. (2024). Real-World Evaluation of Lipid Testing Rate and Treatment Target Attainment Among High-Risk Patients: Post Release of the 2018 AHA/ACC Practice Guidelines. Journal of clinical lipidology. 18(4). e494–e495.

Kloner, Robert A., et al.. (2023). Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data. The Journal of Sexual Medicine. 20(1). 38–48. 22 indexed citations

Butzner, Michael, Martin S. Maron, Ethan J. Rowin, et al.. (2022). Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. The American Journal of Cardiology. 174. 120–125. 6 indexed citations

Butzner, Michael, Martin S. Maron, Ethan J. Rowin, et al.. (2021). Clinical Diagnosis of Hypertrophic Cardiomyopathy Over Time in the United States (A Population-Based Claims Analysis). The American Journal of Cardiology. 159. 107–112. 15 indexed citations

Grabner, Michael, et al.. (2021). Cost-Effectiveness of a Proteomic Test for Preterm Birth Prediction. ClinicoEconomics and Outcomes Research. Volume 13. 809–820. 9 indexed citations

Agatep, Barnabie, Bruce J. Schrader, Felix W. Frueh, et al.. (2013). Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. The Pharmacogenomics Journal. 14(3). 272–280. 35 indexed citations

Bowlin, Steven J., et al.. (2013). Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents. Mayo Clinic Proceedings. 88(2). 139–148. 32 indexed citations

Tse, Sze Man, Scott L. Charland, Eric J. Stanek, et al.. (2013). Statin use in asthmatics on inhaled corticosteroids is associated with decreased risk of emergency department visits. Current Medical Research and Opinion. 30(4). 685–693. 20 indexed citations

Malone, Daniel C., et al.. (2012). PRM26 The Use of Claims-Based CHA2DS2-VASc and ATRIA Scores to Predict Stroke/Systemic Embolism and Bleeding Rates Among Anticoagulated Patients With Atrial Fibrillation (AFIB) in a Pharmacy-Benefit Management (PBM) Environment. Value in Health. 15(7). A464–A464. 1 indexed citations

10.

Stanek, Eric J., Christopher Sanders, Katherine Johansen Taber, et al.. (2012). Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey. Clinical Pharmacology & Therapeutics. 91(3). 450–458. 319 indexed citations

11.

Tang, W.H. Wilson, et al.. (2012). EFFECT OF NIACIN AND EZETIMIBE ON SERUM PARAOXONASE AND ARYLESTERASE ACTIVITIES OF HDL CHOLESTEROL. Journal of the American College of Cardiology. 59(13). E1497–E1497. 1 indexed citations

12.

Taylor, G. N., Todd C. Villines, & Eric J. Stanek. (2012). Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. European Heart Journal. 33(23). 2939–2945. 35 indexed citations

13.

Taylor, Allen J., Todd C. Villines, Eric J. Stanek, et al.. (2009). Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness. New England Journal of Medicine. 361(22). 2113–2122. 480 indexed citations

14.

Charland, Scott L., Mark J. Cziraky, Ralph Quimbo, et al.. (2008). Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events. Journal of clinical lipidology. 2(5). 343–353. 6 indexed citations

15.

Taylor, Allen J. & Eric J. Stanek. (2008). Flushing and the HDL-C response to extended-release niacin. Journal of clinical lipidology. 2(4). 285–288. 6 indexed citations

16.

Sarawate, Chaitanya, Mark J. Cziraky, Eric J. Stanek, et al.. (2007). Achievement of optimal combined lipid values in a managed care setting: Is a new treatment paradigm needed?. Clinical Therapeutics. 29(1). 196–209. 10 indexed citations

17.

McGovern, Mark E., et al.. (2004). 820-5 Once-daily niacin extended-release/lovastatin combination is effective and safe for treatment of dyslipidemia associated with metabolic syndrome. Journal of the American College of Cardiology. 43(5). A486–A487. 2 indexed citations

18.

Stanek, Eric J., et al.. (2000). Preferences for treatment outcomes in patients with heart failure: Symptoms versus survival. Journal of Cardiac Failure. 6(3). 225–232. 128 indexed citations

19.

Cheng, Judy W.M., Scott L. Charland, Leslie M. Shaw, et al.. (1997). Is the Volume of Distribution of Digoxin Reduced in Patients with Renal Dysfunction? Determining Digoxin Pharmacokinetics by Fluorescence Polarization Immunoassay. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 17(3). 584–590. 24 indexed citations

20.

Munger, Mark A., Eric J. Stanek, & Edward A. Panacek. (1991). Focus on fenoldopam: A dopaminergic agonist for severe hypertension. 26(6). 453–460. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact